Background: Nabumetone is biopharmaceutics classification system (BCS) class II drug,
widely used in the treatment of osteoarthritis and rheumatoid arthritis. The most frequently reported
adverse reactions for the drug involve disturbance in gastrointestinal tract, diarrhea, dyspepsia and abdominal
pain. Microemulgel has advantages of microemulsion for improving solubility for hydrophobic
drug. Patent literature had shown that the work for drug has been carried on spray chilling, enteric
coated tablet, and topical formulation which gave an idea for present research work for the
development of transdermal delivery.
Objective: The objective of the present research work was to optimize transdermal microemulgel delivery
for Nabumetone for the treatment of arthritis.
Methods: Oil, surfactant and co-surfactant were selected based on solubility study of the drug. Gelling
agents used were Carbopol 934 and HPMC K100M. Optimization was carried out using 32 factorial
design. Characterization and evaluation were carried out for microemulsion and microemulsion based
Results: Field emission-scanning electron microscopy (FE-SEM) study of the microemulsion revealed
globules of 50-200 nm size. Zeta potential -9.50 mV indicated good stability of microemulsion. Globule
size measured by dynamic light scattering (zetasizer) was 160nm. Design expert gave optimized
batch as F7 which contain 0.2% w/w drug, 4.3% w/w liquid paraffin, 0.71% w/w tween 80, 0.35%
w/w propylene glycol, 0.124% w/w Carbopol 934, 0.187% w/w HPMC K100M and 11.68% w/w water.
In-vitro diffusion study for F7 batch showed 99.16±2.10 % drug release through egg membrane
and 99.15±2.73% drug release in ex-vivo study.
Conclusion: Nabumetone microemulgel exhibiting good in-vitro and ex-vivo controlled drug release